J. Mann

Mar 23, 2024 | kirkusreviews.com | J. Mann |Adam Eli |Michael Bronski

A chronicle of the area comprising the present-day U.S. beginning in 1492 and told through the history of the labor movement. Starting with Christopher Columbus—who “fanboyed [Marco] Polo hard” and set out in search of Asia—and moving forward to the union strikes of 2023, Mann explores the often oppressive, abusive, and bloody history of labor conditions and the merciless rise of capitalism with wit, snark, and comprehensive context.

Aug 29, 2023 | nature.com | J. Mann

AbstractMajor depressive disorder (MDD) is a chronic, generally episodic and debilitating disease that affects an estimated 300 million people worldwide, but its pathogenesis is poorly understood. The heritability estimate of MDD is 30–40%, suggesting that genetics alone do not account for most of the risk of major depression. Another factor known to associate with MDD involves environmental stressors such as childhood adversity and recent life stress.

Jun 20, 2023 | dialnet.unirioja.es | J. Mann |Ricardo Berton |Robert G. Lockie |Brent A. Alvar

Using the Load-Velocity Profile for Predicting the 1RM of the Hexagonal Barbell Deadlift ExerciseAutores: Marcel Lopes Dos Santos, J. Bryan Mann, Ricardo P.B Berton, Brent A. Alvar, Robert G. Lockie, J. Jay DawesLocalización: Journal of strength and conditioning research: the research journal of the NSCA, ISSN 1064-8011, Vol. 37, Nº. 1, 2023, págs.

May 3, 2023 | medscape.com | Drew Ramsey |J. Mann

This transcript has been edited for clarity. Drew Ramsey, MD: Hello, everyone. Welcome back to Medscape Psychiatry. I'm Dr Drew Ramsey. I'm an assistant clinical professor of psychiatry and part of the Medscape Psychiatry editorial board. I'm here with a very special guest. Dr Mann is a professor of translational neuroscience in psychiatry and radiology, and he's also the director of the Columbia Depression Center. Dr Mann, welcome.

Mar 13, 2023 | tandfonline.com | J. Mann

ABSTRACTIntroduction Current treatment of major depressive disorder (MDD) warrants critical reexamination. Initial treatment response rates are modest and drop dramatically after 3 months. Meanwhile, MDD is emerging as the leading cause of disease burden worldwide. Areas covered We searched PubMed (up to June 2021) for randomized controlled trials comparing antidepressant combinations versus monotherapy. We discuss findings from these studies in light of current treatment guidelines for MDD.